PAD: Pharmacist-Administered Injections for Contraception
Study Details
Study Description
Brief Summary
The purpose of this study is to see if it is a feasible arrangement to have women receive their second and third birth control injection (with Depo-Provera) at a pharmacy compared with receiving it a Planned Parenthood Clinic. Compliance with returning for injections as well as patient satisfaction with the method, providers, and location where injection was received will be assessed and compared between the two sites. The hypothesis is that there will be no difference in return rates for injections at either the pharmacy or the clinic site.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Detailed Description
Women who want to use or are currently using Depo-Provera for contraception will be randomized to receive their next two injections either back at the Planned Parenthood clinic or at a local pharmacy where pharmacists are trained to give injections. After each injection, women will be asked to complete a questionnaire to assess their attitudes about the method of birth control, their providers, and the location where they received the injection.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Pharmacy Women receive their second and third depot-medroxyprogesterone acetate injections at the pharmacy by clinical pharmacists |
Other: Pharmacist-administered
women will receive their injections at a pharmacy by a clinical pharmacist
Other Names:
|
| Active Comparator: Planned Parenthood clinic Women receive their second and third depot-medroxyprogesterone acetate injections per usual care at their Planned Parenthood clinic. |
Other: clinic-administered injections
women will return for their injections to the clinic where recruitment took place. They will receive one at 3 months and 6 months.
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Compliance in returning for 3 month and 6 month injections [3 months and 6 months after first injection]
Secondary Outcome Measures
- Attitudes about clinical setting [3 months and 6 months]
Eligibility Criteria
Criteria
Inclusion Criteria:
- At least 18 y.o., English speaking/reading, presenting to Planned Parenthood to use Depo Provera (restarting, first use, or continuing use)
Exclusion Criteria:
- Under 18 years of age, English illiterate (reading and verbal)
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Planned Parenthood of Central North Carolina | Chapel Hill | North Carolina | United States | 27514 |
Sponsors and Collaborators
- University of North Carolina, Chapel Hill
- Pfizer
Investigators
- Principal Investigator: Carla Picardo, MD, MPH, Dept. of Social Medicine, University of North Carolina
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 05-EPID-52